Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for reducing visual loss

A composition and drug technology, applied in the direction of drug combination, drug delivery, pharmaceutical formulation, etc.

Inactive Publication Date: 2018-04-17
EDGE THERAPEUTICS
View PDF21 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, it raises the question whether there is a specific time of day to administer antihypertensive drugs for optimal therapeutic outcome (Jonas JB et al., Am.J.Ophthalmol.142(1), 144-145(2006))
[0063] Despite Availability of Therapeutics, One of the Biggest Barriers to Controlling Glaucoma Is Adherence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for reducing visual loss
  • Compositions and methods for reducing visual loss
  • Compositions and methods for reducing visual loss

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0449] Embodiment 1. The effect of nimodipine preparation on glaucoma patients

[0450] A test formulation containing a microparticulate nimodipine formulation with a uniform particle size distribution will be prepared by combining a polymer solution (eg, a 50-50 glycolide-lactide blend) with a solvent in the presence of nimodipine. The mixture is added to a surfactant-containing aqueous solution to form an emulsion, and the solvent is extracted to produce a flowable microparticle nimodipine formulation. The initial drug loading will be 65%, ie, 65% nimodipine and 35% polymer. The average particle size will be about 52 μm.

[0451] Microparticulate nimodipine formulations can be combined with additional therapeutic agents (eg, prostaglandin analogs, Rho kinase inhibitors) and pharmaceutical carriers to form pharmaceutical compositions of the described invention. A vehicle such as saline (hydroxypropylmethylcellulose (HPMC) in phosphate buffered saline (PBS)) can be mixed wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The described invention provides a method for reducing visual loss and for treating one or more of adverse consequence of an eye disease, including abnormal intraocular pressure, retinal vascular disease, retinal ganglion cell death, or a combination thereof in order to reduce visual loss. The method entails providing a flowable particulate composition that contains a particulate formulation comprising a plurality of particles of uniform size distribution, a therapeutic amount of a therapeutic agent selected from a voltage-gated calcium channel antagonist, an endothelin receptor antagonist, ora combination thereof, and optionally an additional therapeutic agent, wherein the particles are of uniform size distribution, and wherein each particle comprises a matrix; and a pharmaceutically acceptable carrier.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to US Provisional Application No. 62 / 168,588, filed May 29, 2015, which is hereby incorporated by reference in its entirety. technical field [0003] The described invention relates to compositions, systems, and methods for reducing vision loss and for treating one or more adverse consequences of eye disease, including abnormal intraocular pressure, retinal vascular disease, and retinal ganglion cell death, in order to reduce vision loss method. Background of the invention [0004] glaucoma [0005] Glaucoma, a retinal vascular disease, is the most common optic neuropathy, the second most common cause of blindness, and the most common cause of preventable visual disability worldwide (Chua B. and Goldberg I, Expert Rev Ophthalmol 2010; 5(5 ); 627-36). It encompasses a spectrum of progressive optic neuropathies characterized by pathological degeneration of unmyelinated r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4422A61K9/08A61P27/06
CPCA61K9/1647A61K31/4422A61K31/5575A61K45/06A61K9/0048A61K9/0051A61P27/02A61P27/06A61P27/10A61P43/00A61K2300/00A61K9/08
Inventor R.L.麦克唐纳
Owner EDGE THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com